MedDataX Logo

A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers

NCT ID: NCT01637285

Last Updated: 2015-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to further evaluate the PK characteristics of PF-04856883.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859

NCT02766621

Healthy
COMPLETED PHASE1

A Study to Assess Pharmacokinetics of PF-04965842 and Its Metabolites and Effect of Probenecid in Healthy Participants

NCT03937258

Healthy
COMPLETED PHASE1

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

NCT03492697

Healthy Subjects
COMPLETED PHASE1

A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults

NCT05907395

Healthy Participants
COMPLETED PHASE1

Pharmacokinetics And Tolerability Of Subcutaneous Administration Of PF 04236921 In Healthy Volunteers

NCT01166555

Healthy
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-04856883 Treatment Arm 1

Group Type EXPERIMENTAL

PF-04856883

Intervention Type BIOLOGICAL

Dose A

PF-04856883 Treatment Arm 2

Group Type EXPERIMENTAL

PF-04856883

Intervention Type BIOLOGICAL

Dose B

PF-04856883 Treatment Arm 3

Group Type EXPERIMENTAL

PF-04856883

Intervention Type BIOLOGICAL

Dose C

PF-04856883 Treatment Arm 4

Group Type EXPERIMENTAL

PF-04856883

Intervention Type BIOLOGICAL

Dose D

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-04856883

Dose A

Intervention Type BIOLOGICAL

PF-04856883

Dose B

Intervention Type BIOLOGICAL

PF-04856883

Dose C

Intervention Type BIOLOGICAL

PF-04856883

Dose D

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New Haven Clinical Research Unit

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B1111005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.
NCT01989143 COMPLETED PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects
NCT03351751 COMPLETED PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PF-06842874 in Healthy Participants
NCT04124653 COMPLETED PHASE1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.
NCT06532383 COMPLETED PHASE1
A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults
NCT05890105 COMPLETED PHASE1
Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects
NCT02485769 COMPLETED PHASE1
Pharmacokinetics of PN-232 in Healthy Volunteers
NCT04819620 COMPLETED PHASE1
A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects
NCT03230383 COMPLETED PHASE1
Microdose Pharmacokinetic Study of PRX-P4-003 In Healthy Volunteers
NCT04638803 COMPLETED EARLY_PHASE1
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
NCT02228395 COMPLETED PHASE1
A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants
NCT06227975 COMPLETED PHASE1
Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects
NCT02609139 COMPLETED PHASE1
Multiple-Dose Study of VGX-1027 in Healthy Subjects
NCT00760396 COMPLETED PHASE1
Phase 1 Study of PRX019 in Healthy Adult Volunteers
NCT06699680 RECRUITING PHASE1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects
NCT03217604 COMPLETED PHASE1
Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants
NCT04099563 COMPLETED PHASE1
A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy
NCT04839393 COMPLETED PHASE1
Multiple Dose Study in Healthy Volunteers to Assess Safety, Pharmacokinetics and Pharmacodynamics of PF 03882845
NCT00856258 TERMINATED PHASE1
A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects
NCT01626976 COMPLETED PHASE1
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
NCT06137729 TERMINATED PHASE1
A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers
NCT01002963 COMPLETED PHASE1
A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765
NCT01820936 COMPLETED PHASE1
Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571
NCT03092232 COMPLETED PHASE1
A Study to Learn How Different Forms of the Study Medicine Called PF-07976016 Are Taken Up Into the Blood in Healthy Adults
NCT06670170 COMPLETED PHASE1
A Comparison Of The Pharmacokinetics Of PF-04191834 Following Single Dose Administration Of A Dispersion Formulation And A Suspension Formulation In Healthy Volunteers
NCT01265732 WITHDRAWN PHASE1